Amira Pharma commences AM152 Phase 1 study
Amira Pharma Clinical Development vice president Isabelle DeArmond said that they are excited to begin their journey exploring the therapeutic value of AM152, a potentially novel anti-fibrotic agent.
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.